Recode Therapeutics
Clinical trials sponsored by Recode Therapeutics, explained in plain language.
-
New drug targets rare lung disease in early trial
Disease control CompletedThis study tested an experimental drug called RCT1100 in 14 adults with primary ciliary dyskinesia (PCD) caused by a specific gene change (DNAI1). PCD makes it hard for the lungs to clear mucus, leading to frequent infections. The goal was to see if RCT1100 is safe and can improv…
Phase: PHASE1 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated May 26, 2026 07:35 UTC
-
New hope for rare lung disease: experimental drug RCT1100 tested in 7 adults
Disease control CompletedThis early-stage study tested an experimental drug called RCT1100 in 7 adults with primary ciliary dyskinesia (PCD), a rare genetic lung disease caused by DNAI1 gene mutations. The main goal was to check safety and tolerability, while also looking for signs that the drug might he…
Phase: PHASE1 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New study observes lung health in rare disease patients
Knowledge-focused CompletedThis study observed 31 adults with primary ciliary dyskinesia (PCD) and healthy volunteers to measure lung function, mucus clearance, and quality of life. Researchers aimed to establish normal values and better understand the disease. No treatment was given; the goal was to gathe…
Sponsor: ReCode Therapeutics • Aim: Knowledge-focused
Last updated May 26, 2026 07:24 UTC